Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Quest Diagnostics    DGX

QUEST DIAGNOSTICS

(DGX)
  Report
Delayed Quote. Delayed Nyse - 12/02 04:10:00 pm
124.38 USD   -1.03%
11/27QUEST DIAGNOSTICS : Form4
PU
11/24QUEST DIAGNOSTICS : Form4
PU
11/24QUEST DIAGNOSTICS : Media Statement about COVID-19 Testing
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Quest Diagnostics : Form4

10/19/2020 | 04:35pm EST

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or

Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person *

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

RUSCKOWSKI STEPHEN H

QUEST DIAGNOSTICS INC [ DGX ]

__X__ Director

_____ 10% Owner

(Last)

(First)

(Middle)

3. Date of Earliest Transaction (MM/DD/YYYY)

__X__ Officer (give title below) _____ Other (specify below)

500 PLAZA DRIVE

10/16/2020

Chairman, CEO and President

(Street)

4. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

SECAUCUS, NJ 07094

_X _ Form filed by One Reporting Person

(City)

(State)

(Zip)

___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security

2. Trans. Date

2A. Deemed

3. Trans. Code

4. Securities Acquired (A)

5. Amount of Securities Beneficially Owned

6.

7. Nature

(Instr. 3)

Execution

(Instr. 8)

or Disposed of (D)

Following Reported Transaction(s)

Ownership

of Indirect

Date, if any

(Instr. 3, 4 and 5)

(Instr. 3 and 4)

Form:

Beneficial

Direct (D)

Ownership

or Indirect

(Instr. 4)

(A) or

(I) (Instr.

Code

V

Amount

(D)

Price

4)

Common Stock

10/16/2020

M(1)

291997

A

$66.51

529744

D

Common Stock

10/16/2020

S(1)

291997

D

$120

237747

D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of

2.

3. Trans.

3A. Deemed

4. Trans.

5. Number of

6. Date Exercisable and

7. Title and Amount of

8. Price of

9. Number of

10.

11. Nature

Derivate Security

Conversion

Date

Execution

Code

Derivative Securities

Expiration Date

Securities Underlying

Derivative

derivative

Ownership

of Indirect

(Instr. 3)

or Exercise

Date, if any

(Instr. 8)

Acquired (A) or

Derivative Security

Security

Securities

Form of

Beneficial

Price of

Disposed of (D)

(Instr. 3 and 4)

(Instr. 5)

Beneficially

Derivative

Ownership

Derivative

(Instr. 3, 4 and 5)

Owned

Security:

(Instr. 4)

Security

Following

Direct (D)

Amount or

Date

Expiration

Reported

or Indirect

Code

V

(A)

(D)

Exercisable

Date

Title

Number of

Transaction(s)

(I) (Instr.

Shares

(Instr. 4)

4)

Non-Qualifed

M (1)

(2)

Common

Stock Option

$66.51

10/16/2020

291997

2/25/2026

291997.0

$66.51

0

D

Stock

(right to buy)

Explanation of Responses:

  1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on July 24, 2020.
  2. The options vested in three annual installments beginning with the first on February 25, 2017, the second on February 25, 2018 and the final on February 25, 2019.

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer

Other

RUSCKOWSKI STEPHEN H

500 PLAZA DRIVEXChairman, CEO and President SECAUCUS, NJ 07094

Signatures

/s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Stephen H. Rusckowski

**Signature of Reporting Person

10/19/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

  • If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  • Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Quest Diagnostics Incorporated published this content on 19 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 October 2020 20:34:05 UTC


© Publicnow 2020
All news about QUEST DIAGNOSTICS
11/27QUEST DIAGNOSTICS : Form4
PU
11/24QUEST DIAGNOSTICS : Form4
PU
11/24QUEST DIAGNOSTICS : Media Statement about COVID-19 Testing
PU
11/23QUEST DIAGNOSTICS : Leading Black Clergy Announce Historic Partnership to Addres..
PU
11/23QUEST DIAGNOSTICS : Teams Up with Two Health Systems to Deliver High-Value, Inno..
PR
11/20A $10 Covid-19 Test? Walmart Heirs Back Startup Developing At-Home Tests
DJ
11/19QUEST DIAGNOSTICS INC : Other Events (form 8-K)
AQ
11/18QUEST DIAGNOSTICS : Declares Quarterly Cash Dividend
PR
11/17Quest Diagnostics reports rise in turnaround time on COVID-19 testing demand ..
RE
11/17QUEST DIAGNOSTICS : Media Statement about COVID-19 Testing
PU
More news
Financials (USD)
Sales 2020 9 077 M - -
Net income 2020 1 276 M - -
Net Debt 2020 2 961 M - -
P/E ratio 2020 13,4x
Yield 2020 1,78%
Capitalization 16 762 M 16 762 M -
EV / Sales 2020 2,17x
EV / Sales 2021 2,11x
Nbr of Employees 47 000
Free-Float 61,9%
Chart QUEST DIAGNOSTICS
Duration : Period :
Quest Diagnostics Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QUEST DIAGNOSTICS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 141,00 $
Last Close Price 124,38 $
Spread / Highest target 21,4%
Spread / Average Target 13,4%
Spread / Lowest Target -0,31%
EPS Revisions
Managers
NameTitle
Stephen H. Rusckowski Chairman, President & Chief Executive Officer
Mark J. Guinan Chief Financial Officer & Executive Vice President
Jay G. Wohlgemuth Chief Medical Officer, Senior VP-R&D, Medical
Gabrielle Wolfson SVP, Chief Information & Digital Officer
Gail R. Wilensky Independent Director